Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 28

Sort by

Sort Order Select

Journal Articles

Impact of Large Cells and Ki-67% on Outcomes in Patients with Newly Diagnosed Marginal Zone Lymphoma - Results from a Multicenter Cohort Study

Narendranath Epperla, Natalie S. Grover, Kaitlin Annunzio, Marcus P Watkins, Pallawi Torka, Reem Karmali, Andrea Carolina Anampa-Guzmán, Timothy S. Oh, Heather Reves, Montreh Tavakkoli, Emily Hansinger, Beth Christian, Colin Thomas, Stefan K. Barta, Praveen Ramakrishnan Geethakumari, Nancy L. Bartlett, Geoffrey P. Shouse, Adam J Olszewski

Blood (2023) 142 (Supplement 1): 266.

https://doi.org/10.1182/blood-2023-185152

Published: 2023

Journal Articles

Impact of Diagnosis to Treatment Interval on Outcomes in Patients with Newly Diagnosed Marginal Zone Lymphoma - a US Multisite Study

Narendranath Epperla, Kaitlin Annunzio, Geoffrey P. Shouse, Natalie S. Grover, Pallawi Torka, Marcus P Watkins, Andrea Carolina Anampa-Guzmán, Timothy S. Oh, Heather Reves, Montreh Tavakkoli, Emily Hansinger, Beth Christian, Colin Thomas, Stefan K. Barta, Praveen Ramakrishnan Geethakumari, Reem Karmali, Nancy L. Bartlett, Adam J Olszewski

Blood (2023) 142 (Supplement 1): 5159.

https://doi.org/10.1182/blood-2023-185205

Published: 2023

Journal Articles

Incidence of Invasive Fungal Infections in CAR T-Cell Therapy Recipients: A Single-Center Retrospective Analysis

Blood (2023) 142 (Supplement 1): 6921.

https://doi.org/10.1182/blood-2023-186596

Published: 2023

Journal Articles

Utilization and Barriers to Stem Cell Transplantation in Relapsed/Refractory Hodgkin Lymphoma: A ‘Real-World’ Study of Treatment Patterns and Outcomes at a Safety-Net Versus a Tertiary Academic Hospital

Sharlene Dong, Heather Reves, Yu-Lun Liu, Radhika Kainthla, Aimaz Afrough, Julio Alvarenga, Larry D. Anderson, Jr., Stephen S. Chung, Robert H. Collins, Gurbakhash Kaur, Adeel Khan, Kiran Achut Kumar, Yazan F. Madanat, Heather R Wolfe, Elif Yilmaz, Farrukh T. Awan, Praveen Ramakrishnan Geethakumari

Blood (2023) 142 (Supplement 1): 2417.

https://doi.org/10.1182/blood-2023-188033

Published: 2023

Journal Articles

Impact of Maintenance Rituximab Following First-Line Systemic Therapy on Outcomes in Patients with Marginal Zone Lymphoma: Real-World Evidence from 10 US Centers

Blood (2023) 142 (Supplement 1): 5147.

https://doi.org/10.1182/blood-2023-185182

Published: 2023

Journal Articles

Allogeneic Stem Cell Transplant and CD30 Directed CART Cell Therapies Are Associated with Improved Survival in Classical Hodgkin Lymphoma Refractory or Intolerant to Brentuximab Vedotin and Anti-PD-1 Therapy: Real World Analysis from 14 U.S. Academic Centers

Blood (2023) 142 (Supplement 1): 900.

https://doi.org/10.1182/blood-2023-182385

Published: 2023

Journal Articles

Ultra-Hypofractionated Involved Site Radiation Therapy (ISRT) As Salvage or Bridging Therapy in Aggressive Non-Hodgkin Lymphomas

Tanooha Veeramachaneni, Xingzhe Li, Neil Desai, Heather R Wolfe, Elif Yilmaz, Farrukh T. Awan, Robert H. Collins, Robert Timmerman, Praveen Ramakrishnan Geethakumari, Kiran Achut Kumar

Blood (2023) 142 (Supplement 1): 6283.

https://doi.org/10.1182/blood-2023-191089

Published: 2023

Journal Articles

Outcomes in Patients with Classical Hodgkin Lymphoma Refractory or Intolerant to Brentuximab Vedotin and Anti-PD-1 Therapy: Real World Analysis from 14 U.S. Academic Centers

Blood (2023) 142 (Supplement 1): 3061.

https://doi.org/10.1182/blood-2023-181056

Published: 2023

Journal Articles

Predictors of Cytokine Release Syndrome and Neurotoxicity in Patients with Large B-Cell Lymphoma and Their Impact on Survival

Blood (2023) 142 (Supplement 1): 355.

https://doi.org/10.1182/blood-2023-181181

Published: 2023

Journal Articles

Do Monoclonal Antibody Therapies Improve 'Real-World' Outcomes of COVID-19 in Patients with Lymphoid Malignancies? the UT Southwestern Experience

Aishwarya Sannareddy, Heather Reves, Kefyalew Jaleta, Ramyakumari .Ramiahsankarasubramanian, Hetalkumari Patel, Madhusudhanan Narasimhan, Larry D. Anderson, Jr., Aimaz Afrough, Stephen S. Chung, Robert H. Collins, Gurbakhash Kaur, Kiran A Kumar, Yazan F. Madanat, Madhuri Vusirikala, Farrukh T. Awan, Alagarraju Muthukumar, Praveen Ramakrishnan Geethakumari

Blood (2022) 140 (Supplement 1): 5203–5205.

https://doi.org/10.1182/blood-2022-171001

Published: 2022

Journal Articles

Treatment Patterns and Outcomes of Peripheral T-Cell Lymphoma (PTCL) Patients Treated at a Safety-Net Hospital Versus a Tertiary Academic Institution: Does Consolidative Autologous Stem Cell Transplantation (ASCT) Make a Difference?

Meredith Jackson, Heather Reves, Tanushree Prasad, Akshat M Patel, Aimaz Afrough, Larry D. Anderson, Jr., Stephen S. Chung, Robert H. Collins, Gurbakhash Kaur, Kiran A Kumar, Yazan F. Madanat, Madhuri Vusirikala, Farrukh T. Awan, Praveen Ramakrishnan Geethakumari

Blood (2022) 140 (Supplement 1): 5188–5189.

https://doi.org/10.1182/blood-2022-170517

Published: 2022

Journal Articles

Prognostic Impact of Comorbidities on Outcomes of Patients (pts) with Relapsed or Refractory Large B-Cell Lymphoma (r/r LBCL) Treated with Chimeric Antigen Receptor T-Cell Therapy (CART)

Blood (2022) 140 (Supplement 1): 4636–4638.

https://doi.org/10.1182/blood-2022-169452

Published: 2022

Journal Articles

CTX110 Allogeneic CRISPR-Cas9-Engineered CAR T Cells in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 1 Dose Escalation Carbon Study

Blood (2022) 140 (Supplement 1): 10303–10306.

https://doi.org/10.1182/blood-2022-166432

Published: 2022

Journal Articles

Impact of Bridging Therapy on Infectious Complications Post CAR T-Cell Therapy: The UT Southwestern Experience

Akshat M Patel, Brian Lue, Heather Reves, Aimaz Afrough, Larry D. Anderson, Jr., Stephen S. Chung, Robert H. Collins, Gurbakhash Kaur, Kiran A Kumar, Yazan F. Madanat, Madhuri Vusirikala, Farrukh T. Awan, Jeffrey M. Tessier, Praveen Ramakrishnan Geethakumari

Blood (2022) 140 (Supplement 1): 12793–12795.

https://doi.org/10.1182/blood-2022-158778

Published: 2022

Journal Articles

Post-Transplant Cyclophosphamide Associated with Increased Early Mixed Donor Chimerism in Myeloid Malignancies; A Single-Center Experience

Fieke W. Hoff, Prapti A. Patel, Stephen S. Chung, Naveen Premnath, Jude Khatib, Mirjana Tadic-Ovcina, Abeer AhmedRabie, Debra Helton, Jaime Shahan, Courtney Dryden, Hetalkumari Patel, Afrough Aimaz, Praveen Ramakrishnan Geethakumari, Robert H. Collins, Madhuri Vusirikala, Yazan F. Madanat

Blood (2022) 140 (Supplement 1): 4749–4750.

https://doi.org/10.1182/blood-2022-166756

Published: 2022

Journal Articles

Single-Agent Rituximab and Ultra-Low-Dose Adaptive Radiotherapy for the Treatment of Indolent Non-Hodgkin Lymphoma

Meredith Jackson, Sean All, Samantha Brocklehurst, Neil B Desai, Jennifer L Shah, Syed M Rizvi, Farrukh T. Awan, Praveen Ramakrishnan Geethakumari, Kiran A Kumar

Blood (2021) 138 (Supplement 1): 4510.

https://doi.org/10.1182/blood-2021-154354

Published: 2021

Journal Articles

Evaluating the Impact of Therapy Related Healthcare Team Burden on Selection of Novel Therapies for Chronic Lymphocytic Leukemia and Lymphoid Malignancies

Maishara Muquith, Heather Reves, Gurbakhash Kaur, Yazan F. Madanat, Praveen Ramakrishnan Geethakumari, Ankit Kansagra, Prapti Patel, Larry D. Anderson, Jr., Madhuri Vusirikala, Robert H. Collins, Farrukh T. Awan

Blood (2021) 138 (Supplement 1): 4015.

https://doi.org/10.1182/blood-2021-154058

Published: 2021

Journal Articles

Hypofractionated Low-Dose Total Skin Electron Beam Therapy for Primary Cutaneous T-Cell Lymphoma: Analysis of Efficacy and Toxicity

Sofia F Yi, Akshat M Patel, Syed M Rizvi, Praveen Ramakrishnan Geethakumari, Jennifer L Shah, Neil B Desai, Heather W Goff, Kiran A Kumar

Blood (2021) 138 (Supplement 1): 1372.

https://doi.org/10.1182/blood-2021-153958

Published: 2021

Journal Articles

CAR T-Cell Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): A 'Real-World' Analysis of Patterns of Failure and Role of Bridging Therapy

Revathi Ravella, BA, Elizabeth Ren Zhang-Velten, MD PhD, Farrukh T Awan, MD, Syed M Rizvi, MD, Jennifer L Shah, MD, Neil B Desai, MD MHS, Praveen Ramakrishnan Geethakumari, MD MS, Kiran A Kumar, MD MBA

Blood (2020) 136 (Supplement 1): 22–23.

https://doi.org/10.1182/blood-2020-141445

Published: 2020

Journal Articles

Predictive Factors and Outcomes for Ibrutinib Therapy in Relapsed/Refractory Marginal Zone Lymphoma: A Multicenter Cohort Study

Blood (2020) 136 (Supplement 1): 35–36.

https://doi.org/10.1182/blood-2020-135870

Published: 2020

NARROW

Impact of Large Cells and Ki-67% on Outcomes in Patients with Newly Diagnosed Marginal Zone Lymphoma - Results from a Multicenter Cohort Study

Impact of Diagnosis to Treatment Interval on Outcomes in Patients with Newly Diagnosed Marginal Zone Lymphoma - a US Multisite Study

Incidence of Invasive Fungal Infections in CAR T-Cell Therapy Recipients: A Single-Center Retrospective Analysis

Utilization and Barriers to Stem Cell Transplantation in Relapsed/Refractory Hodgkin Lymphoma: A ‘Real-World’ Study of Treatment Patterns and Outcomes at a Safety-Net Versus a Tertiary Academic Hospital

Impact of Maintenance Rituximab Following First-Line Systemic Therapy on Outcomes in Patients with Marginal Zone Lymphoma: Real-World Evidence from 10 US Centers

Allogeneic Stem Cell Transplant and CD30 Directed CART Cell Therapies Are Associated with Improved Survival in Classical Hodgkin Lymphoma Refractory or Intolerant to Brentuximab Vedotin and Anti-PD-1 Therapy: Real World Analysis from 14 U.S. Academic Centers

Ultra-Hypofractionated Involved Site Radiation Therapy (ISRT) As Salvage or Bridging Therapy in Aggressive Non-Hodgkin Lymphomas

Outcomes in Patients with Classical Hodgkin Lymphoma Refractory or Intolerant to Brentuximab Vedotin and Anti-PD-1 Therapy: Real World Analysis from 14 U.S. Academic Centers

Predictors of Cytokine Release Syndrome and Neurotoxicity in Patients with Large B-Cell Lymphoma and Their Impact on Survival

Do Monoclonal Antibody Therapies Improve 'Real-World' Outcomes of COVID-19 in Patients with Lymphoid Malignancies? the UT Southwestern Experience

Treatment Patterns and Outcomes of Peripheral T-Cell Lymphoma (PTCL) Patients Treated at a Safety-Net Hospital Versus a Tertiary Academic Institution: Does Consolidative Autologous Stem Cell Transplantation (ASCT) Make a Difference?

Prognostic Impact of Comorbidities on Outcomes of Patients (pts) with Relapsed or Refractory Large B-Cell Lymphoma (r/r LBCL) Treated with Chimeric Antigen Receptor T-Cell Therapy (CART)

CTX110 Allogeneic CRISPR-Cas9-Engineered CAR T Cells in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 1 Dose Escalation Carbon Study

Impact of Bridging Therapy on Infectious Complications Post CAR T-Cell Therapy: The UT Southwestern Experience

Post-Transplant Cyclophosphamide Associated with Increased Early Mixed Donor Chimerism in Myeloid Malignancies; A Single-Center Experience

Single-Agent Rituximab and Ultra-Low-Dose Adaptive Radiotherapy for the Treatment of Indolent Non-Hodgkin Lymphoma

Evaluating the Impact of Therapy Related Healthcare Team Burden on Selection of Novel Therapies for Chronic Lymphocytic Leukemia and Lymphoid Malignancies

Hypofractionated Low-Dose Total Skin Electron Beam Therapy for Primary Cutaneous T-Cell Lymphoma: Analysis of Efficacy and Toxicity

CAR T-Cell Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): A 'Real-World' Analysis of Patterns of Failure and Role of Bridging Therapy

Predictive Factors and Outcomes for Ibrutinib Therapy in Relapsed/Refractory Marginal Zone Lymphoma: A Multicenter Cohort Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only